The FDA has recommended that Quviviq be classified as a controlled substance and it is anticipated to be available to patients in May 2022, following scheduling by the US Drug Enforcement Administration. Martine Clozel, MD and Chief Scientific Officer of Idorsia, commented: “After more than 20 ...